Cert Medical Oncology(SA) Phys Practice Questions - Sub-specialty Certificate In Medical Oncology Of The College Of Physicians Of South Africa Exam

Access More Questions

A 62-year-old postmenopausal female presents with de novo metastatic ER-positive, HER2-negative breast cancer involving multiple bone lesions and asymptomatic subcentimeter lung nodules. She has an ECOG performance status of 0. Which of the following represents the preferred first-line systemic management?

A CDK4/6 inhibitor (e.g., Ribociclib or Abemaciclib) combined with a non-steroidal aromatase inhibitor (Letrozole or Anastrozole) Dose-dense AC (doxorubicin and cyclophosphamide) chemotherapy for 6 cycles Single-agent Fulvestrant 500 mg intramuscular injection monthly Single-agent Tamoxifen 20 mg oral daily

Correct Answer:

A CDK4/6 inhibitor (e.g., Ribociclib or Abemaciclib) combined with a non-steroidal aromatase inhibitor (Letrozole or Anastrozole)

Access more questions from this quiz

Continue to Cert Medical Oncology(SA) Phys Practice Questions - Sub-specialty Certificate in Medical Oncology of the College of Physicians of South Africa Exam for more practice questions and the full quiz experience.

Access More Questions